Chimeric Therapeutics Limited
Appendix 4E
Preliminary Final Report

1. Company details

Name of entity:	Chimeric Therapeutics Limited
ABN:	68 638 835 828
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025

2. Results for announcement to the market

				$
Loss from ordinary activities after tax	up	80.3%	to	18,809,512
Loss for the year	up	80.3%	to	18,809,512

3. Distributions

No dividends have been paid or declared by the group for the current financial year. No dividends were paid for the previous financial year.

4. Explanation of results

The group reported a loss for the year ended 30 June 2026 of $18,809,512 (30 June 2025: $10,430,424), largely driven by the impairment expense comprised $9,753,092 relating to the CLTX intellectual property following the return of the programme to City of Hope, and $519,716 relating to the CDH-17 intellectual property following the post-reporting-date clinical developments assessed as an adjusting event.

At 30 June 2026, the group's net liabilities were $7,722,773 (30 June 2025: net assets $1,974,514) with cash reserves of $800,145 (30 June 2025: $5,757,474). The group reported nil revenue (30 June 2025: 3,968,525).

5. Net tangible liabilities per security

	30 June 2026 Cents	30 June 2025 Cents
Net tangible liabilities per ordinary security	**(14.58)**	(45.01)

6. Changes in controlled entities

There have been no changes in controlled entities during the year ended 30 June 2026.

7. Other information required by Listing Rule 4.3A

a. Details of individual and total dividends or distributions and dividend or distribution payments:	N/A
b. Details of any dividend or distribution reinvestment plans:	N/A
c, Details of associates and joint ventures entities:	N/A
d. Other information:	N/A

8. Audit

The financial statements of Chimeric Therapeutics Limited (the group) are currently in the process of being audited. The directors expect the Audited financial statements along with unmodified opinion with a material uncertainty related to going concern is expected to be released by the end of September 2026.

Contents

General information

The financial statements cover Chimeric Therapeutics Limited as a group consisting of Chimeric Therapeutics Limited and the entities it controlled at the end of, or during, the year.

The financial statements are presented in Australian dollars.

Chimeric Therapeutics Limited is a company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office	Principal place of business
Level 3, 62 Lygon Street Carlton VIC 3053	Level 3, 62 Lygon Street Carlton VIC 3053

The financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2026. The directors have the power to amend and reissue the financial statements.

Chimeric Therapeutics Limited
Statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	Consolidated 30 June 2026 $	30 June 2025 $
Revenue			
Revenue from contracts with customers	2	**-**	3,968,525
Costs associated with revenue		**-**	(846,763)
Gross profit		**-**	3,121,762
Other income	3	**-**	8,624,060
Other gains/(losses)	3	**107,403**	(22,990)
Expenses			
General and administrative expenses		**(4,602,329)**	(6,445,356)
Research and development expenses		**(3,415,506)**	(14,347,814)
Impairment of intellectual property	4	**(10,272,808)**	-
Share-based payments expenses		**(337,537)**	(1,086,254)
Operating loss		**(18,520,777)**	(10,156,592)
Finance income	3	**39,232**	48,009
Finance expenses	3	**(305,827)**	(211,032)
Finance costs - net		**(266,595)**	(163,023)
Loss before income tax expense		**(18,787,372)**	(10,319,615)
Income tax expense		**(22,140)**	(110,809)
Loss after income tax expense for the year		**(18,809,512)**	(10,430,424)
Other comprehensive (loss)/income			
Items that may be reclassified subsequently to profit or loss			
Exchange differences on translation of foreign operations		**(73,978)**	326,334
Other comprehensive (loss)/income for the year, net of tax		**(73,978)**	326,334
Total comprehensive loss for the year		**(18,883,490)**	(10,104,090)
		Cents	**Cents**
Earnings per share for loss from continuing operations			
Basic earnings per share	10	**(60.97)**	(77.15)
Diluted earnings per share	10	**(60.97)**	(77.15)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Chimeric Therapeutics Limited
Statement of financial position
As at 30 June 2026

	Note	Consolidated 30 June 2026 $	30 June 2025 $
Assets			
Current assets			
Cash and cash equivalents	5	**800,145**	5,757,474
Trade and other receivables	5	**29,122**	4,551,105
Other current assets		**194,978**	217,833
Total current assets		**1,024,245**	10,526,412
Non-current assets			
Intangible assets	6	**254,499**	11,044,759
Total non-current assets		**254,499**	11,044,759
Total assets		**1,278,744**	21,571,171
Liabilities			
Current liabilities			
Trade and other payables	5	**7,983,758**	10,870,872
Other financial liabilities		**-**	3,562,406
Employee benefits obligation	6	**225,047**	180,040
Convertible notes and warrants	8	**679,845**	-
Total current liabilities		**8,888,650**	14,613,318
Non-current liabilities			
Other financial liabilities		**109,313**	4,982,421
Employee benefits obligation	6	**3,554**	918
Total non-current liabilities		**112,867**	4,983,339
Total liabilities		**9,001,517**	19,596,657
Net (liabilities)/assets		**(7,722,773)**	1,974,514
Equity			
Share capital	7	**80,413,400**	70,162,110
Other reserves	7	**6,433,203**	8,146,404
Accumulated losses		**(94,569,376)**	(76,334,000)
Total (deficiency)/equity		**(7,722,773)**	1,974,514

The above statement of financial position should be read in conjunction with the accompanying notes

Chimeric Therapeutics Limited
Statement of changes in equity
For the year ended 30 June 2026

Consolidated	Share capital $	Other reserves $	Accumulated losses $	Total equity $
	Attributable to owners of Chimeric Therapeutics Limited			
Balance at 1 July 2024	**63,510,730**	**5,518,895**	**(66,559,557)**	**2,470,068**
Loss after income tax expense for the year	-	-	(10,430,424)	(10,430,424)
Other comprehensive income for the year, net of tax	-	326,334	-	326,334
Total comprehensive income/(loss) for the year	**-**	**326,334**	**(10,430,424)**	**(10,104,090)**
Transactions with owners in their capacity as owners:				
Contributions of equity	6,643,247	-	-	6,643,247
Transaction costs and tax	(1,125,737)	-	-	(1,125,737)
Options issued	-	1,558,998	-	1,558,998
Forfeiture of unlisted options	-	(182,376)	-	(182,376)
Conversion of options	1,600	-	-	1,600
Expiration of options	-	(296,451)	296,451	-
Lapse of options	-	(359,530)	359,530	-
Issue of performance rights	-	193,631	-	193,631
Conversion of performance rights	172,270	(172,270)	-	-
Issue of shares under share purchase agreement	960,000	-	-	960,000
Shares to be issued per Board and management placement	-	1,559,173	-	1,559,173
Balance at 30 June 2025	**70,162,110**	**8,146,404**	**(76,334,000)**	**1,974,514**

Consolidated	Share capital $	Other reserves $	Accumulated losses $	Total equity $
	Attributable to owners of Chimeric Therapeutics Limited			
Balance at 1 July 2025	**70,162,110**	**8,146,404**	**(76,334,000)**	**1,974,514**
Loss after income tax expense for the year	-	-	(18,809,512)	(18,809,512)
Other comprehensive loss	-	(73,978)	-	(73,978)
Total comprehensive loss for the year	**-**	**(73,978)**	**(18,809,512)**	**(18,883,490)**
Transactions with owners in their capacity as owners:				
Contributions of equity	8,783,595	-	-	8,783,595
Transaction costs and tax	(965,978)	-	-	(965,978)
Options issued	-	823,415	-	823,415
Expiration of options	-	(574,136)	574,136	-
Forfeiture of options	-	(284,547)	-	(284,547)
Issue of performance rights	-	17,329	-	17,329
Forfeiture of performance rights	-	(62,111)	-	(62,111)
Issue of shares under share purchase agreement	565,000	-	-	565,000
Issue of convertible notes conversion	260,000	-	-	260,000
Issue of shares consideration for professional services rendered	49,500	-	-	49,500
Shares issued per Board and management placement	1,559,173	(1,559,173)	-	-
Balance at 30 June 2026	**80,413,400**	**6,433,203**	**(94,569,376)**	**(7,722,773)**

The above statement of changes in equity should be read in conjunction with the accompanying notes

	Note	Consolidated 2026 $	2025 $
Cash flows from operating activities			
Receipts from customers		**-**	3,968,525
Payments to suppliers (inclusive of GST)		**(15,216,687)**	(15,464,605)
Research and development tax incentive received		**4,497,887**	4,172,342
Interest received		**39,232**	48,009
Interest and other finance costs paid		**(103,868)**	-
Net cash outflow from operating activities		**(10,783,436)**	(7,275,729)
Cash flows from investing activities			
Payments of license fee liabilities		**(249,338)**	-
Net cash outflow from investing activities		**(249,338)**	-
Cash flows from financing activities			
Proceeds from issue of shares and other equity securities	7	**8,791,958**	8,204,420
Share issue transaction costs		**(896,429)**	(572,009)
Proceeds from borrowings		**1,785,005**	4,061,589
Repayment of borrowings		**(2,500,000)**	(1,562,000)
Repayment of financial liabilities		**(1,665,000)**	-
Transaction costs related to loans and borrowings		**(184,089)**	(86,000)
Proceeds from issue of convertible notes		**750,000**	-
Net cash inflow from financing activities		**6,081,445**	10,046,000
Net (decrease)/increase in cash and cash equivalents		**(4,951,329)**	2,770,271
Cash and cash equivalents at the beginning of the financial year		**5,757,474**	3,053,001
Effects of exchange rate changes on cash and cash equivalents		**(6,000)**	(65,798)
Cash and cash equivalents at the end of the financial year	5	**800,145**	5,757,474

1. Segment information

Management has determined, based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions, that the group has one reportable segment being the research, development and commercialisation of health technologies. The segment details are therefore fully reflected in the body of the financial statements.

2. Revenue from contracts with customers

	Consolidated	
Revenue from contracts with customers	**30 June 2026 $**	30 June 2025 $
Revenue recognised over time	**-**	3,968,525

During the period ended 30 June 2025, the group entered into an arrangement to advance clinical development of CHM CDH-17 CAR-T.

3. Other income and expense items

(a) Other income

	30 June 2026 $	30 June 2025 $
Research and development tax incentive (i)	**-**	8,624,060
	-	8,624,060

(i) Recognition of R&D tax incentive income
At 30 June 2026, the group has not recognised an accrual for its FY2026 research and development tax incentive claim (2026 estimate: $4.5 million, 2025: $4,497,887) due to uncertainty regarding the claim as the estimate cannot be reliably measured at this time.

(b) Other gains/(losses)

	30 June 2026 $	30 June 2025 $
Net loss on disposal of property, plant and equipment	**-**	(292)
Net foreign exchange gain/(loss)	**297,248**	(114,657)
Fair value adjustment on financing agreements	**(189,845)**	91,959
	107,403	(22,990)

3. Other income and expense items (continued)

(c) Finance income and expenses

	30 June 2026 $	30 June 2025 $
Finance income		
Interest income from financial assets held for cash management purposes	**39,232**	48,009
Finance income	**39,232**	48,009
Finance expenses		
Interest and finance charges paid for financial liabilities not at fair value	**(287,957)**	(209,275)
Finance expenses in relation to financing activities	**(17,870)**	(1,757)
Finance expenses	**(305,827)**	(211,032)
Net finance costs	**(266,595)**	(163,023)

4. Impairment of intellectual property

	Consolidated 2026 $	Consolidated 2025 $
Impairment of intellectual property (i)	**10,272,808**	-

(i) Impairment of intellectual property
On 27 February 2026, the group announced a portfolio streamline with the return of CHM Chlorotoxin (CLTX) CAR T-cell therapy asset to City of Hope and the asset has been fully impaired.

On 19 August 2026, the group announced it ceased the enrolment in CHM CDH-17 Phase 1 trial following dose-limiting toxicities. As this is an adjusting subsequent event, the asset has been fully impaired at 30 June 2026.

5. Financial assets and financial liabilities

(a) Cash and cash equivalents

	30 June 2026 $	30 June 2025 $
Current assets		
Cash at bank and on hand	**800,145**	5,757,474

(i) Reconciliation to cash flow statement

The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year as follows:

	30 June 2026 $	30 June 2025 $
Balances as above	**800,145**	5,757,474
Balances per statement of cash flows	**800,145**	5,757,474

5. Financial assets and financial liabilities (continued)

(ii) Classification as cash equivalents

Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition and are repayable with 24 hours notice with no loss of interest.

(iii) Risk exposure

The maximum exposure to credit risk at the end of the reporting year is the carrying amount of each class of cash and cash equivalents mentioned above.

(b) Trade and other receivables

		30 June 2026			30 June 2025	
	Current $	**Non-current $**	**Total $**	Current $	Non-current $	Total $
Accrued receivables	**-**	**-**	**-**	4,497,887	-	4,497,887
Other receivables	**29,122**	**-**	**29,122**	53,218	-	53,218
	29,122	**-**	**29,122**	4,551,105	-	4,551,105

(c) Trade and other payables

		30 June 2026			30 June 2025	
	Current $	**Non-current $**	**Total $**	Current $	Non-current $	Total $
Trade payables	**5,399,875**	**-**	**5,399,875**	6,566,448	-	6,566,448
Accrued expenses	**472,723**	**-**	**472,723**	1,569,051	-	1,569,051
R&D advance	**1,904,134**	**-**	**1,904,134**	2,523,589	-	2,523,589
Other payables	**207,026**	**-**	**207,026**	211,784	-	211,784
	7,983,758	**-**	**7,983,758**	10,870,872	-	10,870,872

6. Non-financial assets and liabilities

(a) Intangible assets

	Chlorotoxin $	CDH-17 $	CORE-NK $	Total $
At 1 July 2024				
Cost	14,670,492	719,863	331,909	15,722,264
Accumulated amortisation and impairment	(3,558,059)	(119,201)	(34,632)	(3,711,892)
Net book amount	**11,112,433**	**600,662**	**297,277**	**12,010,372**
Year ended 30 June 2025				
Opening net book amount	11,112,433	600,662	297,277	12,010,372
Amortisation charge	(903,751)	(40,473)	(21,389)	(965,613)
Closing net book amount	**10,208,682**	**560,189**	**275,888**	**11,044,759**
At 30 June 2025				
Cost	14,670,492	719,863	331,909	15,722,264
Accumulated amortisation and impairment	(4,461,810)	(159,674)	(56,021)	(4,677,505)
Net book amount	**10,208,682**	**560,189**	**275,888**	**11,044,759**
Year ended 30 June 2026				
Opening net book amount	10,208,682	560,189	275,888	11,044,759
Amortisation charge	(455,590)	(40,473)	(21,389)	(517,452)
Impairment	(9,753,092)	(519,716)	-	(10,272,808)
Closing net book amount	**-**	**-**	**254,499**	**254,499**
At 30 June 2026				
Cost	14,670,492	719,863	331,909	15,722,264
Accumulated amortisation and impairment	(14,670,492)	(719,863)	(77,410)	(15,467,765)
Net book amount	**-**	**-**	**254,499**	**254,499**

The group's intellectual property is measured at initial cost, less any accumulated amortisation and impairment losses.

6. Non-financial assets and liabilities (continued)

(i) Chlorotoxin CAR-T technology

The group previously recognised the Intellectual Property "Chlorotoxin CAR-T technology" through the acquisition of a worldwide exclusive licence developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California. The licence agreement between City of Hope and Chimeric is perpetual.

The Chlorotoxin CAR-T technology is amortised over a period of 16 years, being management's assessed useful life of the intangible asset.

On 27 February 2026, the group announced a portfolio streamline with the return of CHM Chlorotoxin (CLTX) CAR T-cell therapy asset to City of Hope. As a result the asset has been fully impaired.

(ii) CDH-17 CAR-T technology

The group has recognised the Intellectual Property "CDH-17" through the acquisition of a worldwide exclusive licence developed at University of Pennsylvania, a world-renowned Cell Therapy Centre based in Philadelphia, Pennsylvania. The licence agreement between University of Pennsylvania and Chimeric is perpetual.

On 19 August 2026, the group announced it ceased the enrolment in CHM CDH-17 Phase 1 trial following dose-limiting toxicities. As a result an adjusting event was recognised at 30 June 2026 to fully impair the asset.

(iii) CORE-NK

The group has recognised the Intellectual Property "CORE-NK" through the acquisition of an exclusive licence developed at Case Western Reserve University, a private research university based in Cleveland, Ohio. The licence agreement between Case Western Reserve University and Chimeric is perpetual.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licence fee paid and the value of equity issued to Case Western Reserve University in respect of the licence agreement.

CORE-NK is amortised over a period of 15 years, being management's assessed useful life of the intangible asset.

(b) Employee benefit obligations

		30 June 2026			30 June 2025	
	Current	**Non-current**	**Total**	Current	Non-current	Total
	$	**$**	**$**	$	$	$
Leave obligations	**225,047**	**3,554**	**228,601**	180,040	-	180,040

(i) Leave obligations

The leave obligations cover the group's liabilities for annual leave which are classified as short-term benefits.

The current portion of this liability includes all of the accrued annual leave and pro-rata payments employees are entitled to in certain circumstances. The provision of $228,601 (2025: $180,040) is presented as current, since the group does not have an unconditional right to defer settlement for any of these obligations. However, based on past experience, the group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months.

7. Equity

(a) Share capital

	Notes	**2026 Shares**	2025 Shares	**2026 $**	2025 $
Ordinary shares fully paid	note 7(a)(i)	**54,728,067**	2,015,194,149	**80,413,400**	70,162,110

(i) Movements in ordinary shares:

	Number of shares	**Total $**
Balance at 1 July 2024	**876,055,712**	**63,510,730**
Issue of shares under the share purchase agreement at $0.014 (2024-08-02)	10,714,286	150,000
Conversion of performance rights at $0.038 (2024-08-30)	2,456,267	93,338
Conversion of performance rights at $0.019 (2024-08-30)	4,385,120	78,932
Issue of shares under the share purchase agreement at $0.013 (2024-09-20)	11,538,462	150,000
Issue of shares through a Private Placement at $0.008 (2024-10-24)	69,990,973	559,928
Issue of shares under the share purchase agreement at $0.008 (2024-11-05)	20,000,000	160,000
Issue of shares under the share purchase agreement at $0.008 (2024-12-10)	25,000,000	200,000
Issue of shares through a Private Placement at $0.008 (2024-12-09)	555,009,026	4,440,072
Issue of shares under the share purchase agreement at $0.008 (2025-02-12)	20,000,000	100,000
Issue of shares under the share purchase agreement at $0.004 (2025-03-17)	25,000,000	100,000
Issue of shares Private Placement at $0.005 (2025-04-30)	197,203,052	986,015
Issue of shares under the share purchase agreement at $0.003 (2025-05-09)	33,333,334	100,000
Issue of shares Private Placement at $0.004 (2025-05-26)	164,307,917	657,232
Conversion of options at $0.008 (2025-05-28)	200,000	1,600
Less: Transaction costs arising on share issues	-	(1,125,737)
Balance 30 June 2025	**2,015,194,149**	**70,162,110**

	Number of shares	**Total $**
Balance at 1 July 2025	**2,015,194,149**	**70,162,110**
Issue of shares Private Placement at $0.004 (2025-07-25)	1,092,679,329	4,370,717
Issue of shares under the share purchase agreement at $0.004 (2025-07-25)	141,250,000	565,000
Issue of shares Private Placement at $0.004 (2025-08-07)	5,435,254	21,741
Issue of shares Private Placement at $0.004 (2025-10-10)	387,577,500	1,550,310
Issue of shares Private Placement at $0.003 (2025-12-31)	466,666,665	1,400,000
Issue of shares Private Placement at $0.003 (2026-01-07)	309,900,722	929,702
Consolidation 100:1 (2026-04-29)*	(4,374,515,663)	-
Issue of shares on conversion of convertible notes (2026-05-01)	733,333	55,000
Issue of shares Private Placement at $0.3 (2026-05-04)	6,900,993	2,070,298
Issue of shares on conversion of convertible notes (2026-05-11)	512,820	50,000
Issue of shares consideration for professional services rendered at $0.158 (2026-05-11)	313,291	49,500
Issue of shares on conversion of convertible notes (2026-05-20)	533,333	50,000
Issue of shares on conversion of convertible notes (2026-06-01)	733,333	55,000
Issue of shares on conversion of convertible notes (2026-06-11)	813,008	50,000
Less: Transaction costs arising on share issues	-	(965,978)
Balance 30 June 2026	**54,728,067**	**80,413,400**

*On the 29th of April 2026 the group announced the consolidation of issued capital on a 1 for 100 basis.

7. Equity (continued)

(b) Other reserves

The following table shows a breakdown of the Statement of financial position line item 'other reserves' and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table.

	Note	Shares to be issued $	Share-based payments $	Foreign currency translation $	Total other reserves $
At 1 July 2024		**-**	**5,848,609**	**(329,714)**	**5,518,895**
Currency translation differences		-	-	326,334	326,334
Other comprehensive loss		**-**	**-**	**326,334**	**326,334**
Transactions with owners in their capacity as owners					
Issue of options	7(b)(ii)	-	1,558,998	-	1,558,998
Expiration of options		-	(296,451)	-	(296,451)
Issue of performance rights		-	193,631	-	193,631
Conversion of performance rights		-	(172,270)	-	(172,270)
Forfeiture of unlisted options		-	(182,376)	-	(182,376)
Lapse of options	7(b)(ii)	-	(359,530)	-	(359,530)
Shares to be issued per placement		1,559,173	-	-	1,559,173
At 30 June 2025		**1,559,173**	**6,590,611**	**(3,380)**	**8,146,404**
Currency translation differences		-	-	(73,978)	(73,978)
Other comprehensive loss		**-**	**-**	**(73,978)**	**(73,978)**
Transactions with owners in their capacity as owners					
Issue of options	7(b)(ii)	-	823,415	-	823,415
Expiration of options		-	(574,136)	-	(574,136)
Forfeiture of unlisted options		-	(284,547)	-	(284,547)
Issue of performance rights		-	17,329	-	17,329
Forfeiture of performance rights		-	(62,111)	-	(62,111)
Shares to be issued per placement		(1,559,173)	-	-	(1,559,173)
At 30 June 2026		**-**	**6,510,561**	**(77,358)**	**6,433,203**

(i) Nature and purpose of other reserves

Share-based payments
The share-based payment reserve records items recognised as expenses relating to equity payments including the valuation of share options issued to key management personnel, other employees and eligible contractors.

Foreign currency translations
Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income or loss and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

7. Equity (continued)

(ii) Movements in options

Details	Number of options	Share based payment reserve total $
Balance at 1 July 2024	**161,878,469**	**5,732,196**
		-
Forfeiture of unlisted options	(5,816,912)	(182,376)
Issue of unlisted options	155,772,195	1,558,998
Issue of listed options	822,203,051	-
Conversion of listed options	(200,000)	-
Expiration of unlisted options	(2,750,000)	(296,451)
Cancellation of unlisted options	(3,140,003)	(359,530)
Balance at 30 June 2025	**1,127,946,800**	**6,452,837**
Issue of listed options	1,831,416,683	156,550
Issue of unlisted options	210,561,000	193,456
Expiration of listed options	(2,613,253,051)	-
Expiration of unlisted options	(4,261,789)	(574,136)
Forfeiture of unlisted options	(307,017)	(284,547)
Expense for share-based payments for options previously issued	-	473,409
Consolidation 100:1	(531,870,260)	-
Balance 30 June 2026	**20,232,366**	**6,417,569**

8. Convertible notes and warrants

	Consolidated	
	2026	2025
	$	$
Current liabilities		
Convertible Notes	**661,214**	-
Warrants	**18,631**	-
	679,845	-

During the period ended 30 June 2026, the group raised funds by entering into a convertible note facility. Shareholder approval was granted on the 17 April 2026 and on the 18 April 2026 tranche 1 of the facility was issued consisting of 750 convertible notes that convert at $1,000 per note and 350 warrant that exercise at $1,000 per warrant. At 30 June 2026 there were 490 convertible notes available and 350 warrants available for conversion.

9. Events since the end of the financial year

On 6 July 2026, Mr Eric Sullivan resigned as the Non-Executive Director of the group.

On 17 July 2026, the group issued 650 convertible notes at $1,000 per note under Tranche 2 of the Convertible Note Facility and received proceeds of $650,000.

On 29 July 2026, the group announced they received $1.62 million from Endpoints capital under a funding facility secured against Chimeric's FY26 Research and Development tax incentive with interest charged at commercial rates.

9. Events since the end of the financial year (continued)

On 19 August 2026, the group announced it ceased the enrolment in CHM CDH-17 Phase 1 trial following dose-limiting toxicities. At 30 June 2026 there were indicators of impairment and as a result of the ceasing of enrolment, an adjusting event was recognised at 30 June 2026 to impair the CDH-17 intellectual property down to nil. The other financial liabilities for contingent consideration related to this asset have also been reduced as the probability of milestones now being met has been assessed as nil. As a result, the group expects a major cost reduction across headcount, manufacturing and trial-related costs. These actions are estimated to save approximately $4 million annually after initial termination costs.

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the group's operations, the results of those operations, or the group's state of affairs in future financial years.

10. Loss per share

(a) Reconciliations of earnings used in calculating loss per share

	Consolidated	
	2026	2025
	$	$
Earnings per share for loss from continuing operations		
Loss after income tax	**(18,809,512)**	(10,430,424)

(b) Weighted average number of shares used as the denominator

	Consolidated	
	2026	2025
	Number	Number
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	**30,850,997**	13,519,242

The weighted average number of ordinary shares used in the calculation of basic and diluted loss per share has been retrospectively adjusted to reflect the 100:1 share consolidation completed during the year.

On the basis of the group's losses, the outstanding options as at 30 June 2026 are considered to be anti-dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.

11. Interests in other entities

(a) Subsidiaries

The group’s subsidiaries at 30 June 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

		Ownership interest	
Name	**Place of business / Country of incorporation**	**2026 %**	2025 %
Chimeric Therapeutics (USA) Inc	United States	100%	100%